Key facts
- It has raised $3.5M; the latest was Early Stage VC ($3.5M) in Mar 2026.
- Notable investors include High-Tech Gründerfonds, Mission BioCapital, LBBW Venture Capital, BaseLaunch, L-Bank.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Umlaut (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Umlaut (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Umlaut (Biotechnology)
Developer of RNA-based therapeutics designed to target cancer and inflammatory diseases by modulating RNA modifications. The company offers small molecule approaches focused on tRNA modification and regulation of cellular signaling pathways, enabling healthcare and research communities to address disease progression beyond traditional protein-targeting methods.
- Sector
- Healthcare
- HQ
- Heidelberg, Germany
- Founded
- 2024
- Employees
- 4
- Website
- umlaut.bio/
- Ownership
- Privately Held (backing)
Umlaut (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Umlaut (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Umlaut (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.